Rakesh Popat

27PUBLICATIONS
119CO-AUTHORS
Predictive and prognostic markersTumour immunologyGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (27)

|Jun 18, 2026
The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

|May 20, 2026
Real-World Evaluation of Talquetamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM): An International Myeloma Working Group Immunotherapy Registry Real-World Analysis.

|Mar 02, 2026
Efficacy and Safety of Belantamab Mafodotin with Bortezomib plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: The DREAMM-6 Arm B Trial.

Rakesh Popat, Bradley Augustson, Paul Cannell

|Dec 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study.

Rakesh Popat, Meral Beksac, Meletios A Dimopoulos

|Apr 02, 2025
Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study.

Carlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang

|Feb 18, 2025
Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma.

Martin F Kaiser, Pieter Sonneveld, David A Cairns

Pageof 5

Frequent Collaborators

11 joint publications

Kwee Yong

4 joint publications

Gordon Cook

3 joint publications

Selina J Chavda

3 joint publications

María-Victoria Mateos